Back to today’s briefing

Story perspectives

Immunotherapy Boosts Survival for OCCC Patients with Mutation

7/4/2025

26 2

Summary

Story summary

Patients with PPP2R1A mutations in ovarian clear cell carcinoma (OCCC) experience a remarkable boost in survival rates after immunotherapy, according to researchers at The University of Texas MD Anderson Cancer Center. While those without the mutation survive an average of just 9.2 months, mutation carriers thrive for a median of 66.9 months, suggesting a promising avenue for enhancing cancer treatment.

1 of 1

Story summary

Patients with PPP2R1A mutations in ovarian clear cell carcinoma (OCCC) experience a remarkable boost in survival rates after immunotherapy, according to researchers at The University of Texas MD Anderson Cancer Center. While those without the mutation survive an average of just 9.2 months, mutation carriers thrive for a median of 66.9 months, suggesting a promising avenue for enhancing cancer treatment.